Ge. Knight et G. Burnstock, THE EFFECTS OF PURINE COMPOUNDS ON THE ISOLATED AORTA OF THE FROG RANA-TEMPORARIA, British Journal of Pharmacology, 117(5), 1996, pp. 873-878
1 In the isolated aorta of the frog, Rana temporaria, adenosine concen
tration-dependently, endothelium-independently relaxed adrenaline pre-
constricted vessels. None of the adenosine analogues including D-5'-(N
-ethylcarboxamide) adenosine (NECA), R- and S-N-6-(2-phenylisopropyl)
adenosine (R-and S-PIA) and 2-chloroadenosine (2-CA), or the more sele
ctive A(1), A(2) and A(3) agonists cyclopentyladenosine (CPA), CGS 216
80 and N-6-(3-iodobenzyl) adenosine-5'-N-methylcarboxamide (IB-MECA) r
espectively, had any effect. 2 The non-selective adenosine antagonist,
8-p-sulphophenyl-theophylline (8-pSPT; 30 mu M) failed to inhibit ade
nosine relaxations, as did N-G-nitro-L-arginine methyl ester (L-NAME;
0.1 mM) and indomethacin (30 mu M). 3 Adenosine 5'-triphosphate (ATP),
alpha,beta-methylene ATP (alpha,beta-MeATP), beta,gamma-methylene ATP
(beta,gamma-MeATP), 2-methylthio ATP (2-MeSATP) and uridine 5'-tripho
sphate (UTP) all concentration-dependently contracted the frog aorta.
ATP and alpha,beta-MeATP were equipotent and more potent than UTP and
beta,gamma-MeATP; 2-MeSATP had little activity. 4 The P-2-purinoceptor
antagonist, suramin (0.1 mM) inhibited contractions to alpha,beta-MeA
TP but not to ATP. Pyridoxalphosphate-6-azophenyl-2',4'-disulphonic ac
id (PPADS; 30 mu M) also inhibited contractions to alpha,beta-MeATP bu
t not to ATP. Contractions to ATP were, however, inhibited by indometh
acin (30 mu M). 5 In conclusion, in the frog aorta there appears to be
a novel subclass of P-1-purinoceptor mediating vasodilatation, althou
gh like the A(3) subclass it is not blocked by methylxanthines; a P-2-
purinoceptor mediates vasoconstriction which resembles a P-2X subtype,
based on the agonist potency of alpha,beta-MeATP being more potent th
an 2-MeSATP (UTP has moderate activity) and PPADS is an effective anta
gonist. There is no evidence for the presence of a P-2Y-purinoceptor,
mediating vasodilatation, in this preparation.